Search Results

You are looking at 1 - 10 of 365 items for :

  • "Ovarian cancer" x
  • Refine by Access: All x
Clear All
Full access

Epithelial Ovarian Cancer

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

O varian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms (∼ 80%) 1 ; however, other less-common pathologic subtypes must

Full access

Indications for Minimally Invasive Surgery for Ovarian Cancer

Ernest S. Han and Mark Wakabayashi

M ore than 21,000 women are estimated to be diagnosed with epithelial ovarian cancer in the United States in 2010, and an estimated 13,850 will die of the disease. 1 Of all gynecologic cancers, ovarian cancer is the most common cause of death. 1

Full access

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes

Ovarian neoplasms consist of several histopathologic entities; treatment depends on the specific tumor type. 1 Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms (about 90%) 2 – 4 ; however, other less common pathologic

Full access

Counterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancer

Maurie Markman

to help oncologists determine the statistically defined likelihood the patient will experience a more- or less-favorable outcome (prognostic testing). In ovarian cancer, validated and useful prognostic tests include tumor grade, surgical stage, volume

Full access

New Issues in Systemic Therapy for Ovarian Cancer

Deborah K. Armstrong

Most patients with ovarian cancer are diagnosed with advanced-stage cancer. Debulking surgery followed by chemotherapy is recommended. The standard front-line regimen is 6 cycles of paclitaxel plus carboplatin, with docetaxel a reasonable

Full access

Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer

Kelsey S. Lau-Min, Anne Marie McCarthy, Katherine L. Nathanson, and Susan M. Domchek

other high-penetrance cancer susceptibility genes for a subset of patients with breast cancer (eg, based on tumor characteristics, age at diagnosis, ancestry, and family history) and all patients diagnosed with ovarian cancer. 2 Despite these

Full access

The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer

Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim

Edited by Kerrin G. Robinson

E . Cancer statistics, 2008 . CA Cancer J Clin 2008 ; 58 : 71 – 96 . 2. Ozols RF Rubin SC Thomas GM . Epithelial ovarian cancer . In: Hoskins WJ, Perez CA, Young RC, et al., eds . Principles and Practice of Gynecologic Oncology. 4th

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

able to: Integrate into professional practice the updates to the NCCN Guidelines for Ovarian Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Ovarian Cancer Disclosure of Relevant Financial

Full access

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer

Ranjit Manchanda, Li Sun, Monika Sobocan, Isabel V. Rodriguez, Xia Wei, Ashwin Kalra, Samuel Oxley, Michail Sideris, Caitlin T. Fierheller, Robert D. Morgan, Dhivya Chandrasekaran, Kelly Rust, Pavlina Spiliopoulou, Rowan E. Miller, Shanthini M. Crusz, Michelle Lockley, Naveena Singh, Asma Faruqi, Laura Casey, Elly Brockbank, Saurabh Phadnis, Tina Mills-Baldock, Fatima El-Khouly, Lucy A. Jenkins, Andrew Wallace, Munaza Ahmed, Ajith Kumar, Elizabeth M. Swisher, Charlie Gourley, Barbara M. Norquist, D. Gareth Evans, and Rosa Legood

Background Ovarian cancer (OC) is the most common cause of gynecologic cancer deaths worldwide annually (324,603 new cases, 206,956 deaths), 1 with approximately 90% of cases being epithelial OC. 2 By 2045, OC cases are predicted to increase

Full access

Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer

Joyce Liu and Ursula Matulonis

. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996 ; 334 : 1 – 6 . 3. Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared